Havemeyer Place’s Sarepta Therapeutics SRPT Stock Holding History

Havemeyer Place’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,794	Closed	-$148K	–	674
2026 Q1	$148K	Buy	+6,794	New	+$131K	0.02%	469

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Havemeyer Place's SRPT Position: Q2 2026 in Review

Havemeyer Place sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 6,794 shares — an estimated $148K sold.

Havemeyer Place first reported a position in SRPT in Q1 2026 and held it in 1 quarter. The position peaked at $148K in Q1 2026. 321 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Havemeyer Place reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
Havemeyer Place sold 6,794 Sarepta Therapeutics shares in Q2 2026, an estimated $148K.
Havemeyer Place first reported a position in Sarepta Therapeutics in Q1 2026 and held it in 1 quarter.
Havemeyer Place's Sarepta Therapeutics position peaked at $148K in Q1 2026.
321 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Havemeyer Place's 13F filing for Q2 2026, filed 13 Aug 2026.